About WAVE Life Sciences (NASDAQ:WVE)
Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on proprietary programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics, as well as a collaboration agreement with Deep Genomics Inc. for identifying novel therapies. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:WVE
CUSIPN/A
Phone65-6236-3388
Debt
Debt-to-Equity Ratio0.02%
Current Ratio7.67%
Quick Ratio7.67%
Price-To-Earnings
Trailing P/E Ratio-11.30
Forward P/E Ratio-12.08
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.70 million
Price / Sales329.07
Cash FlowN/A
Price / CashN/A
Book Value$5.03 per share
Price / Book8.65
Profitability
EPS (Most Recent Fiscal Year)($3.85)
Net Income$-102,030,000.00
Net Margins-2,754.73%
Return on Equity-66.73%
Return on Assets-53.57%
Miscellaneous
Employees168
Outstanding Shares27,990,000
WAVE Life Sciences (NASDAQ:WVE) Frequently Asked Questions
What is WAVE Life Sciences' stock symbol?
WAVE Life Sciences trades on the NASDAQ under the ticker symbol "WVE."
How were WAVE Life Sciences' earnings last quarter?
WAVE Life Sciences (NASDAQ:WVE) issued its quarterly earnings results on Monday, March, 12th. The company reported ($1.09) EPS for the quarter, missing the Zacks' consensus estimate of ($1.00) by $0.09. The firm had revenue of $1.68 million for the quarter, compared to the consensus estimate of $0.63 million. WAVE Life Sciences had a negative net margin of 2,754.73% and a negative return on equity of 66.73%. View WAVE Life Sciences' Earnings History.
When is WAVE Life Sciences' next earnings date?
What price target have analysts set for WVE?
5 brokerages have issued 1-year target prices for WAVE Life Sciences' stock. Their forecasts range from $40.00 to $65.00. On average, they expect WAVE Life Sciences' share price to reach $53.40 in the next twelve months. View Analyst Ratings for WAVE Life Sciences.
Who are some of WAVE Life Sciences' key competitors?
Some companies that are related to WAVE Life Sciences include Puma Biotechnology (PBYI), Horizon Pharma (HZNP), Heron Therapeutics (HRTX), Global Blood Therapeutics (GBT), Portola Pharmaceuticals (PTLA), AnaptysBio (ANAB), Medicines (MDCO), Motif (MTFB), Intercept Pharmaceuticals (ICPT), Corcept Therapeutics (CORT), Esperion Therapeutics (ESPR), Spectrum Pharmaceuticals (SPPI), Arena Pharmaceuticals (ARNA), Aimmune Therapeutics (AIMT), Cambrex (CBM), Insmed (INSM), MyoKardia (MYOK) and Phibro Animal Health (PAHC).
Who are WAVE Life Sciences' key executives?
WAVE Life Sciences' management team includes the folowing people:
- Dr. Paul B. Bolno M.D., MBA, Pres, CEO & Director (Age 44)
- Mr. Keith C. Regnante MBA, Chief Financial Officer (Age 48)
- Mr. Ken Takanashi MBA., CPA, Corp. Sec. & Director (Age 54)
- Dr. Michael A. Panzara M.D., MPH, Franchise Lead of Neurology (Age 51)
- Dr. Takeshi Wada, Scientific Advisor (Age 56)
Has WAVE Life Sciences been receiving favorable news coverage?
Media headlines about WVE stock have been trending somewhat positive recently, Accern reports. Accern identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. WAVE Life Sciences earned a media sentiment score of 0.10 on Accern's scale. They also assigned news articles about the company an impact score of 46.68 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are WAVE Life Sciences' major shareholders?
WAVE Life Sciences' stock is owned by many different of institutional and retail investors. Top institutional investors include
KAGOSHIMA SHINSANGYO SOUSEI INVESTMENT LIMITED PARTNERSHIP
(8.90%) and
KAGOSHIMA SHINSANGYO SOUSEI INVESTMENT LIMITED PARTNERSHIP
(8.90%). Company insiders that own WAVE Life Sciences stock include Chandra Vargeese, Chris Francis, Gregory L Verdine, Keith Regnante, Masaharu Tanaka, Michael A Panzara and Ra Capital Management, Llc. View Institutional Ownership Trends for WAVE Life Sciences.
How do I buy shares of WAVE Life Sciences?
Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is WAVE Life Sciences' stock price today?
One share of WVE stock can currently be purchased for approximately $43.50.
How big of a company is WAVE Life Sciences?
WAVE Life Sciences has a market capitalization of $1.22 billion and generates $3.70 million in revenue each year. The company earns $-102,030,000.00 in net income (profit) each year or ($3.85) on an earnings per share basis. WAVE Life Sciences employs 168 workers across the globe.
How can I contact WAVE Life Sciences?
WAVE Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected]
MarketBeat Community Rating for WAVE Life Sciences (WVE)
MarketBeat's community ratings are surveys of what our community members think about WAVE Life Sciences and other stocks. Vote "Outperform" if you believe WVE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WVE will underperform the S&P 500 over the long term. You may vote once every thirty days.
WAVE Life Sciences (NASDAQ:WVE) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for WAVE Life Sciences in the last 12 months. Their average twelve-month price target is $53.40, suggesting that the stock has a possible upside of 22.76%. The high price target for WVE is $65.00 and the low price target for WVE is $40.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $53.40 | $53.40 | $41.60 | $40.00 |
| Price Target Upside: | 22.76% upside | 28.67% upside | 68.08% upside | 75.05% upside |
WAVE Life Sciences (NASDAQ:WVE) Consensus Price Target History
WAVE Life Sciences (NASDAQ:WVE) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
WAVE Life Sciences (NASDAQ:WVE) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
WAVE Life Sciences (NASDAQ WVE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 53.00%
Institutional Ownership Percentage: 79.38%
WAVE Life Sciences (NASDAQ WVE) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/20/2018 | Chris Francis | Insider | Sell | 21,639 | $55.40 | $1,198,800.60 | |  |
| 2/16/2018 | Keith Regnante | CFO | Sell | 316 | $51.85 | $16,384.60 | | |
| 2/16/2018 | Michael A Panzara | Insider | Sell | 511 | $52.10 | $26,623.10 | | |
| 1/23/2018 | Chandra Vargeese | Insider | Sell | 2,000 | $40.00 | $80,000.00 | | |
| 11/22/2017 | Chandra Vargeese | Insider | Sell | 1,500 | $35.00 | $52,500.00 | | |
| 11/14/2017 | Ra Capital Management, Llc | Director | Buy | 423,398 | $23.34 | $9,882,109.32 | | |
| 9/18/2017 | Masaharu Tanaka | Director | Sell | 20,747 | $24.21 | $502,284.87 | | |
| 7/12/2017 | Michael A Panzara | Insider | Sell | 7,414 | $16.67 | $123,591.38 | 15,336 | |
| 3/29/2017 | Masaharu Tanaka | Director | Sell | 433,825 | $24.91 | $10,806,580.75 | | |
| 6/15/2016 | Gregory L Verdine | Director | Sell | 52,000 | $16.70 | $868,400.00 | 150,079 | |
(Data available from 1/1/2013 forward)
WAVE Life Sciences (NASDAQ WVE) News Headlines
| Source: |
|
WAVE Life Sciences (NASDAQ:WVE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
WAVE Life Sciences (NASDAQ:WVE) Income Statement, Balance Sheet and Cash Flow Statement
WAVE Life Sciences (NASDAQ WVE) Stock Chart for Sunday, April, 22, 2018
Loading chart…
